Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

@article{Raymond2018EfficacyAS,
  title={Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.},
  author={Elizabeth Raymond and Matthew H. Kulke and Shukui Qin and Xianjun Yu and Michael Schenker and A. Millan Cubillo and Wenhui Lou and Jiř{\'i} Tom{\'a}{\vs}ek and Espen Thiis-Evensen and Jianming Xu and Adina Emilia Croitoru and Mustafa Khasraw and Eva Sedl{\'a}{\vc}kov{\'a} and Ivan Borbath and Paul Ruff and Paul E Oberstein and Tetsuhide Ito and Liqun Jia and Pascal Hammel and L Shen and Shailesh Vinayak Shrikhande and Yali Shen and Jozef Sufliarsky and Gazala Naaz Khan and Chigusa Morizane and Salvatore Galdy and Reza Khosravan and Kathrine C. Fernandez and Brad Rosbrook and Nicola Fazio},
  journal={Neuroendocrinology},
  year={2018},
  volume={107 3},
  pages={
          237-245
        }
}
BACKGROUND In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III data. METHODS In this ongoing, open-label, phase IV trial (NCT01525550), patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were… CONTINUE READING
BETA